stockrowTakeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
- Revenue
- +1.71%
- EPS
- −4.35%
- Free cash flow
- +54.9%
- Total debt
- −7.28%
Quarter to September 2026, against a year earlier
Follow TAK
Alert me
Takeda Pharmaceutical Co. (TAK) Free cash flow margin
Takeda Pharmaceutical Co.'s free cash flow margin over the twelve months to 30 September 2026 was 0.00%, down 14.0 percentage points from fiscal 2026 (14.1%). Over the past ten years it has ranged from −3.26% (fiscal 2016) to 26.3% (fiscal 2022); the current reading is higher than 58% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2026 | 14.1% | (0.74) |
| FY2025 | 14.8% | 9.06 |
| FY2024 | 5.73% | (2.82) |
| FY2023 | 8.55% | (17.76) |
| FY2022 | 26.3% | 0.64 |
| FY2021 | 25.7% | 11.55 |
| FY2020 | 14.1% | 2.43 |
| FY2019 | 11.7% | (2.57) |
| FY2018 | 14.3% | 5.46 |
| FY2017 | 8.80% | 12.06 |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| NBIX Neurocrine Biosciences, Inc. compare | 28.1% |
| UTHR United Therapeutics Corporation compare | 27.2% |
| ZTS Zoetis Inc. compare | 24.4% |
| VTRS Viatris Inc. compare | 16.3% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 7.71% |
| ELAN Elanco Animal Health Incorporated compare | 7.55% |
| RDY Dr. Reddy's Laboratories Ltd compare | 2.88% |
| TAK Takeda Pharmaceutical Co. | 0.00% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on TAK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement